Hardy Reed LLC Decreases Position in Elevance Health, Inc. $ELV

Hardy Reed LLC decreased its holdings in Elevance Health, Inc. (NYSE:ELV) by 63.0% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 1,322 shares of the company’s stock after selling 2,254 shares during the quarter. Hardy Reed LLC’s holdings in Elevance Health were worth $427,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Axxcess Wealth Management LLC raised its position in Elevance Health by 27.0% in the 2nd quarter. Axxcess Wealth Management LLC now owns 1,436 shares of the company’s stock valued at $558,000 after purchasing an additional 305 shares in the last quarter. Mutual Advisors LLC grew its position in shares of Elevance Health by 17.0% during the second quarter. Mutual Advisors LLC now owns 2,370 shares of the company’s stock worth $922,000 after buying an additional 345 shares in the last quarter. Arista Wealth Management LLC purchased a new stake in shares of Elevance Health during the second quarter worth approximately $537,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Elevance Health in the second quarter valued at approximately $15,714,000. Finally, International Assets Investment Management LLC acquired a new stake in Elevance Health in the second quarter valued at approximately $38,938,000. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Elevance Health Trading Up 3.1%

NYSE:ELV opened at $346.49 on Friday. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $458.75. The company has a current ratio of 1.54, a quick ratio of 1.56 and a debt-to-equity ratio of 0.70. The stock’s 50 day simple moving average is $352.22 and its 200-day simple moving average is $332.03. The firm has a market cap of $76.47 billion, a P/E ratio of 13.79, a PEG ratio of 1.93 and a beta of 0.50.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, topping the consensus estimate of $3.10 by $0.23. The firm had revenue of $49.31 billion during the quarter, compared to the consensus estimate of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The company’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same period last year, the company earned $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Equities analysts anticipate that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th will be paid a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.0%. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. The ex-dividend date is Tuesday, March 10th. Elevance Health’s dividend payout ratio (DPR) is presently 27.23%.

Elevance Health News Roundup

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Zacks raised its Q4 2027 EPS forecast to $4.75 (from $3.48), a sign that Zacks expects stronger late‑year profitability which could support the stock if sustained. Elevance Health (ELV) on MarketBeat
• Neutral Sentiment: MSN ran a stock‑perspective piece highlighting two reasons to like ELV and one caveat; the article reinforces bullish arguments around Elevance’s scale and business stability but also flags at least one risk investors should weigh. 2 reasons to like ELV (and 1 not so much)
• Negative Sentiment: Zacks issued multiple cuts to near‑term and full‑year estimates — lowering FY2026 (to $25.53 from $29.01), FY2027 (to $28.40 from $31.89) and trimming several Q1/Q2 2026–2027 quarterly forecasts — which signals weaker expected growth in the coming quarters and is a potential headwind for the stock. Zacks Research Lowers Earnings Estimates for Elevance Health

Analyst Upgrades and Downgrades

ELV has been the topic of a number of recent analyst reports. Wall Street Zen downgraded shares of Elevance Health from a “buy” rating to a “hold” rating in a research report on Sunday, February 8th. Sanford C. Bernstein dropped their target price on Elevance Health from $431.00 to $409.00 and set an “outperform” rating on the stock in a report on Friday, January 30th. Royal Bank Of Canada cut Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 price target on the stock. in a research note on Tuesday, February 3rd. Morgan Stanley decreased their price target on Elevance Health from $359.00 to $352.00 and set an “equal weight” rating for the company in a report on Wednesday, December 17th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $332.00 price objective on shares of Elevance Health in a report on Thursday, January 29th. Twelve research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Elevance Health currently has a consensus rating of “Moderate Buy” and an average price target of $390.55.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.